Author(s):
Azoubel, Maria Cecília Fonsêca ; Sarmento, Viviane Almeida ; Lima, Virna Luci Cangussu ; Azoubel, Eduardo ; Bittencourt, Sandro ; Cunha, Fernando Q. ; Ribeiro, Ronaldo A. ; Brito, Gerly Anne de Castro ; Azoubel, Maria Cecília Fonsêca ; Sarmento, Viviane Almeida ; Lima, Virna Luci Cangussu ; Azoubel, Eduardo ; Bittencourt, Sandro ; Cunha, Fernando Q. ; Ribeiro, Ronaldo A. ; Brito, Gerly Anne de Castro
Date: 2013
Origin: Oasisbr
Subject(s): Anti-inflammatory agents; Clinical trial; Dental scaling; toricoxib; Periodontitis; Root planing
Description
p. 1719-1725
Submitted by Suelen Reis (suziy.ellen@gmail.com) on 2013-11-26T12:02:03Z No. of bitstreams: 1 jop%2E2008%2E080019.pdf: 501743 bytes, checksum: b8ee7e9f91e7cbf60e5101a88a1b4c22 (MD5)
Approved for entry into archive by Rodrigo Meirelles (rodrigomei@ufba.br) on 2013-11-26T12:58:32Z (GMT) No. of bitstreams: 1 jop%2E2008%2E080019.pdf: 501743 bytes, checksum: b8ee7e9f91e7cbf60e5101a88a1b4c22 (MD5)
Made available in DSpace on 2013-11-26T12:58:32Z (GMT). No. of bitstreams: 1 jop%2E2008%2E080019.pdf: 501743 bytes, checksum: b8ee7e9f91e7cbf60e5101a88a1b4c22 (MD5) Previous issue date: 2008
Background: This pilot study assessed the effect of short-duration treatment with etoricoxib as adjuvant therapy to scaling and root planing (SRP) on the clinical and radiographic parameters and prostaglandin E2 (PGE2) levels in aggressive periodontitis. Methods: Subjects were randomly allocated to test or control treatment (n = 10 in each group) and submitted to SRP and treatment with etoricoxib, 120 mg/day, or placebo for 7 days. Probing depth, clinical attachment level (CAL), gingival recession, visible plaque index, bleeding on probing, linear distance (LD) from the cemento-enamel junction to the alveolar crest, and analysis of the gray levels were recorded before and 1 month after the therapies. The prostaglandin E2 (PGE2) level in the gingival crevicular fluid (GCF) was measured by radioimmunoassay at the beginning of the study and 7 and 30 days after treatment. Results: No significant difference in the clinical parameters was observed between the groups at the end of the experimental period, although both groups presented significant improvement in all variables examined. There was a decrease in CAL from 5.54 ± 0.47 mm to 3.59 ± 0.53 mm in the test group and from 5.92 ± 1.10 mm to 3.69 ± 0.80 mm in the control group. A significant reduction in PGE2 was found after 7 days of treatment. LD differed between the groups. Conclusion: Etoricoxib did not promote additional improvement in the clinical parameters; however, it produced an initial reduction in the PGE2 levels in the GCF, which could be related to the discrete improvement in the bone condition.
